DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.57
19.41
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
DaShenLin Pharmaceutical Group Co Ltd
Net Income (Common)
DaShenLin Pharmaceutical Group Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Net Income (Common)
ÂĄ1.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
LBX Pharmacy Chain JSC
SSE:603883
|
Net Income (Common)
ÂĄ417.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
6%
|
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Net Income (Common)
ÂĄ1.6B
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
26%
|
|
|
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
|
Net Income (Common)
-ÂĄ188.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Net Income (Common)
ÂĄ90.2m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-12%
|
|
|
A
|
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
|
Net Income (Common)
ÂĄ137.7m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
DaShenLin Pharmaceutical Group Co Ltd
Glance View
DaShenLin Pharmaceutical Group Co., Ltd. is a fascinating entity woven into the intricate fabric of China's rapidly evolving healthcare landscape. Stemming from humble origins, the company has blossomed into a significant player in the pharmaceutical industry. DaShenLin's business model adeptly combines the traditional with the modern, strategically positioning itself across the supply and distribution spectrum. Primarily, it operates through an extensive retail network, boasting a formidable chain of pharmacies thoughtfully dotted across various provinces. These pharmacies are more than mere outlets; they serve as community health sanctuaries offering an array of pharmaceutical products and health consultations. The company's commitment to traditional Chinese medicine sets it apart, further establishing a niche by fusing age-old healing practices with contemporary medicinal needs. The company's revenue streams are as diverse as its product offerings. Predominantly, it derives income from the direct sale of pharmaceuticals, encompassing both Western drugs and traditional Chinese medicines. Additionally, DaShenLin capitalizes on its robust wholesale operations, providing a steady pipeline of medicinal products to regional hospitals and clinics. The company thrives on its comprehensive supply chain, which ensures an uninterrupted flow of goods from production to consumers' hands. With a keen emphasis on quality and efficacy, DaShenLin continuously invests in research and development, fostering innovation within its product lines. This strategic focus not only reinforces consumer trust but also secures its competitive edge within a dynamic market landscape.
See Also
What is DaShenLin Pharmaceutical Group Co Ltd's Net Income (Common)?
Net Income (Common)
1.1B
CNY
Based on the financial report for Sep 30, 2025, DaShenLin Pharmaceutical Group Co Ltd's Net Income (Common) amounts to 1.1B CNY.
What is DaShenLin Pharmaceutical Group Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
2%
Over the last year, the Net Income (Common) growth was 34%. The average annual Net Income (Common) growth rates for DaShenLin Pharmaceutical Group Co Ltd have been 8% over the past three years , 2% over the past five years .